Medical Network News, April 8 Recently, wind released the latest list of 'Top 500 Listed Companies in China's Market Value.' Huada Gene and Lepu Medical's list of doctors' rings, Huada Gene ranked 165th, Lepu Medical ranked 186th, both in the top 200 Strong among.
The top three rankings were Tencent Holdings (3.1276 trillion yuan), Alibaba (2.9268 trillion yuan), and Industrial and Commercial Bank of China (2.1113 billion yuan).
Huada Gene, which has exceeded 100 billion in market value
medical instruments The highest market value, Huada Gene also.
Huada Gene listed on July 5, 2017, with an issue price of 13.64 yuan per share, followed by four consecutive months of rising, N multiple daily limit, the stock price rose to more than 230 yuan per share, and the stock price rose by more than 950% in 2017. A-shares rose for the second year in a row, and the market value rushed to around 110 billion yuan. It has declined since last December. The current stock price is more than 170 yuan, and the price-earnings ratio is 128 times, with a total market value of 67.7 billion.
However, in stark contrast to the madness of the stock price, it is the profitability of Huada. The annual profit is only less than 400 million yuan, and the growth rate has fallen sharply year-on-year.
According to the report of the First Financial Bureau, the controversy over whether or not Huada Genomics is a demon stock has become increasingly fierce. On November 29 last year, Huada Gene Wang Jian responded at the Annual Summit of the First Financial Industry: 'Last night There is a news that the big bubble in China has broken down. Let's see if the bubble at Huada breaks.
The reason why Huada Gene has caused market rush and media popularity is precisely because it also meets two key words: biomedicine and high technology.
According to information from Cypress Blue’s equipment, Huada Genomics disclosed its 2017 annual performance report on the evening of February 13 this year. The company achieved total operating revenue of 2.09 billion yuan in 2017, an increase of 22.39% year-on-year; and the net profit attributable to shareholders of listed companies was 3.95. Billion yuan, a year-on-year increase of 18.86%.
Its 128-fold price-to-earnings ratio is far higher than the average level of the medical device industry. Ultimately it will not be able to maintain such a stock price and market value for a long time. No one can guarantee it.
Lepu Medical, the continuously growing Taurus
If you are concerned about Lepu for a long time, you will find that this is a company that continues to gain recognition in the sauce market. This is reflected in the stock price and market value.
For example, in June 2016, the market value was about 32 billion yuan; in November 2017, the market value was about 42 billion yuan; in April 2018, about 60 billion yuan.
Even now, Lepu’s performance has supported its market value. Compared with 53 medical device listed companies, Lepu’s total market capitalization ranks second, net assets ranks first, net profit ranks first, and gross profit margin ranks The 7th, but the price-earnings ratio is ranked 37th! So to say, Lepu's market value is still a large amount of space theoretically. By 2019 or so, is likely to exceed the BGI gene.
Throughout the 9 years of the listing of Lepu, it has initiated about 30 industry mergers and acquisitions, continuously enriching its own product lines and commercial channels, and the market value is constantly being pushed up by the market.
Medical ring market potential company: Mindray, United Shadows
In addition to the above two top 500 companies, there are two potential market values in the medical circle. enterprise If you are still based on the bottom of the list of the top 500 companies with a value of 26.7 billion, then the two current valuations will exceed this benchmark.
The two companies are Mindray and Ulead.
Among them, Mindray had previously failed to successfully attack the A-shares, and soon restarted the listing plan. The industrial circle's valuation is about 100 billion yuan, and there have been valuations of more than 60 billion yuan.
According to the information just disclosed, Mindray’s revenue in 2017 was 11.17 billion yuan, an increase of 23.72%, net profit was 2.59 billion yuan, and the growth rate was 61.78%!
In the “2017 Unicorn Enterprises List and Trend Research Report” released jointly by the Torch Center of the Ministry of Science and Technology on March 23rd this year, the company’s valuation is US$5 billion.
On September 15 last year, Lianhe was awarded the largest financing in the field of medical equipment in China to date: A round of financing of 3.333 billion yuan, and a post-investment valuation of 33.333 billion yuan.
The round of financing is made by China Life Insurance health The fund and SDIC Innovation Investment Management Co., Ltd. jointly led the investment, China State Capital Venture Capital Fund, CICC Zhide, CITIC Securities, Guokai Kaiyuan, Zhaoyin Telecom and other investment institutions jointly contributed.
As a medical device with great potential for development, the Chinese market is so large that there will be one or two hundred billion worth of companies in the next few years. Let's wait and see, who will become the market value and performance of the future? '.
Appendix: Top 500 Listed Market Value of Chinese Enterprises
